Kodiak Sciences Inc. (NASDAQ:KOD) Stock Has Consensus Price Target of $104.71

Kodiak Sciences Inc. (NASDAQ:KOD) has been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $104.71.

Several analysts have recently issued reports on the stock. Weiss Ratings cut shares of Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. The Goldman Sachs Group started coverage on shares of Kodiak Sciences in a research report on Wednesday, September 30th. They issued a “neutral” rating and a $103.00 price target for the company. HC Wainwright upped their target price on shares of Kodiak Sciences from $96.00 to $126.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Lifesci Capital upped their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a report on Monday, September 28th. Finally, Jefferies Financial Group restated a “buy” rating and set a $112.00 target price on shares of Kodiak Sciences in a report on Monday, September 28th.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker acquired 86,432 shares of Kodiak Sciences stock in a transaction dated Thursday, November 5th. The stock was purchased at an average cost of $98.51 per share, with a total value of $8,514,416.32. Following the completion of the purchase, the director directly owned 20,424,859 shares in the company, valued at approximately $2,012,052,860.09. This trade represents a 0.42% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have acquired 2,188,845 shares of company stock worth $181,326,862. Corporate insiders own 44.40% of the company’s stock.

Hedge Funds Weigh In On Kodiak Sciences

Several large investors have recently bought and sold shares of the stock. KBC Group NV acquired a new position in shares of Kodiak Sciences in the 1st quarter valued at about $39,000. Sterling Capital Management LLC lifted its position in Kodiak Sciences by 850.0% during the third quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock valued at $124,000 after acquiring an additional 1,173 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Kodiak Sciences by 94.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock worth $73,000 after purchasing an additional 936 shares during the last quarter. Simplicity Wealth LLC purchased a new position in Kodiak Sciences in the 3rd quarter valued at approximately $263,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Kodiak Sciences in the third quarter valued at approximately $304,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Price Performance

Shares of NASDAQ KOD opened at $99.30 on Friday. Kodiak Sciences has a 12 month low of $15.83 and a 12 month high of $104.00. The firm’s 50 day simple moving average is $69.56 and its 200-day simple moving average is $43.69. The stock has a market capitalization of $6.24 billion, a price-to-earnings ratio of -23.70 and a beta of 2.02.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). Analysts anticipate that Kodiak Sciences will post -3.97 earnings per share for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.